Deferoxamine mesylate

An iron chelator that binds iron and aluminium; increases HIF-1α transactivation in diabetes by preventing iron-catalyzed reactive oxygen stress.Other Indication Approved (In Vitro) :Deferoxamine mesylate (1 mM; 16 h or 4 weeks) improves HIF-1α function under hypoxic and hyperglycemic conditions and decreases ROS in MEFs cells.Deferoxamine mesylate (100 μM; 24 h) increases InsR expression and activity and also induces an increase in p-Akt/total Akt/PKB levels.Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 or 9 days) inhibits the proliferation of tumor-associated MSCs and bone marrow MSCs.Deferoxamine mesylate (5, 10, 25, 50, 100 μM; 7 days) induces apoptosis of MSCs.Deferoxamine mesylate (10 μM ; 3 days) influencs the expression of adhesion proteins on MSCs.Deferoxamine mesylate (100 μM; 24 h) induces autophagy mediated by the level of HIF-1α in SH-SY5Y cells. (In Vivo) :Deferoxamine mesylate (560.68 mg/per; drip-on; once daily for 21 days) enhances wound healing and increases neovascularization in aged or diabetic mice.Deferoxamine mesylate (200 mg/kg; i.p.; daily for 2 weeks) results in HIF-1α stabilization and increases glucose uptake, hepatic InsR expression, and signaling in vivo.